- Three patent households have been filed to cowl novel hormonal combos: pramlintide-exenatide and glucagon-exenatide – each combos demonstrated promising results in weight problems remedy
- Administering short-acting hormones by a pump empowers the affected person, who can optimize the profit/threat ratio of their remedy
- These formulations is also developed for the remedy of different metabolic ailments akin to NASH (Non-Alcoholic Steato-Hepatitis), sort 2 diabetes or neurodegenerative ailments
LYON, France, Might 26, 2021 (GLOBE NEWSWIRE) — Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical firm specialised within the improvement of progressive formulations of proteins and peptides introduced as we speak that three patent households have been filed for the remedy of metabolic ailments together with weight problems, NASH (Non-Alcoholic Steato-Hepatitis), sort 2 diabetes and neurodegenerative problems. These patents relate to combos of short-acting hormones administered by way of pump. First preclinical outcomes obtained in overweight mice inhabitants by a mix of glucagon-exenatide (BioChaperone® GluExe) present a weight lack of 25% versus 15% with exenatide alone after 14 days of remedy1. A second mixture of pramlintide and exenatide (PramExe), at the moment in improvement, additionally presents promising properties. The pumps used are these already marketed for insulin remedy, and particularly patch-pumps, that are straightforward to make use of and appropriate for this goal. The consumer can alter the maximal tolerable dose and subsequently optimize the profit/threat stability.
“We need to set up a brand new therapeutic paradigm for continual ailments akin to weight problems, permitting sufferers larger management over their remedy,” defined Gérard Soula, Adocia’s CEO. “Our imaginative and prescient is to empower folks by serving to them to regain management of their sickness, by enabling them to regulate doses in actual time with the assistance of contemporary pumps and related gadgets for higher adherence to long-term therapies. That is the place the long run is heading: customized medication and affected person empowerment.”
Adocia is providing a disruptive therapeutic method by infusing short-acting hormones by way of a pump in order that sufferers can simply and shortly alter the doses administered, in distinction to the present mind-set which is to increase the length of motion of hormones to supply weekly injections. One of many disadvantages of long-acting hormones is the impossibility to interrupt the unwanted effects – notably gastrointestinal – which might generally final a number of days after administration. Pharmaco-epidemiological research on the usage of once-weekly GLP-1 hormones in sort 2 diabetes reveal that 48.0% of sufferers cease remedy after one 12 months, whereas 73.2% stopped after two years2.
Pump-infusion opens various views:
- The affected person can steadily improve the dose as really helpful when initiating these hormonal therapies
- The continual infusion permits sufferers to take care of weight reduction impact with out focus peaks that might trigger unwanted effects
- The affected person can cease and begin the remedy on the contact of a button; unwanted effects lower quickly because of the short-acting hormones, remedy may be resumed shortly as soon as these results have subsided
- The affected person has the liberty for a “day-off”, to momentarily pause remedy for larger flexibility on skilled or private events, bettering high quality of life
- Algorithm improvement and machine studying may additionally enhance remedy efficacy and tolerance
“Our experience on diabetes hormones and the potential of insulin pumps led us to develop functions to different continual ailments,” feedback Olivier Soula, Deputy CEO and Director of R&D at Adocia. “Our subsequent goal is to ascertain scientific proof-of-concept with good tolerance and efficacy of PramExe administered by way of pump, whereas being well-accepted by folks affected by weight problems.”
PramExe is a fixed-ratio co-formulation of an amylin analog (pramlintide) and a GLP-1 receptor agonist (exenatide). Pramlintide and exenatide are two hormones marketed for the remedy of diabetes and have already demonstrated individually optimistic results on weight reduction and satiety. Adocia’s innovation lies in combining weight reduction results of those two compounds administered with a wearable pump. Adocia’s PramExe mixture is able to be scientific examined in people.
About weight problems and coverings
Greater than 650 million folks worldwide, are overweight (BMI≥30 kg/m²) based on the official classification of the World Well being Group (WHO), which declares weight problems a continual illness and a serious public well being drawback since 19972. In response to the WHO, 2.8 million folks die every year worldwide on account of being chubby or overweight. At the moment solely 2% of sufferers affected by weight problems are medicated3 and solely hormonal therapies seem as a potential various to bariatric surgical procedure.
Adocia is a clinical-stage biotechnology firm that focuses on the event of progressive formulations of therapeutic proteins and peptides for the remedy of diabetes and metabolic ailments. Within the diabetes discipline, Adocia’s portfolio of injectable therapies is among the many largest and most differentiated of the business, that includes 5 clinical-stage merchandise and a number of other pre-clinical merchandise. The proprietary BioChaperone® technological platform is designed to boost the effectiveness and/or security of therapeutic proteins whereas making them simpler for sufferers to make use of. Adocia customizes BioChaperone® to every protein for a given utility.
Adocia’s scientific pipeline contains 4 novel insulin formulations for prandial remedy of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a mix of basal insulin glargine and speedy performing insulin lispro (BioChaperone® Combo) and one mixture of a prandial insulin with amylin analog pramlintide M1Pram. The scientific pipeline additionally contains an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the remedy of hypoglycemia.
Adocia preclinical pipeline contains bi-hormonal combos for diabetes remedy: two combos of speedy performing insulin analogs and Pramlintide (BioChaperone® Lispro Pram and BioChaperone® Aspart Pram), a mix of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). As well as, there are two bi-hormonal merchandise for the remedy of weight problems: a mix of glucagon and exenatide (BioChaperone® GluExe) and a mix of pramlintide and exenatide (PramExe).
Adocia lately added a preclinical program to its pipeline with a cell remedy initiative centered on improvement of a hydrogel scaffold to be used in folks with sort 1 diabetes. The primary patent utility supporting this program has been filed.
Ph: +33 4 72 610 610
|MC Providers AG
Adocia Press Relations Europe
Ph: +49 89 210 228 0
|The Ruth Group
Adocia Investor Relations USA
Ph.: +1 646 536 7035
This press launch comprises sure forward-looking statements regarding Adocia and its enterprise. Such forward-looking statements are primarily based on assumptions that Adocia considers to be affordable. Nonetheless, there may be no assurance that the estimates contained in such forward-looking statements will probably be verified, which estimates are topic to quite a few dangers together with the dangers set forth within the “Danger Components” part of the Common Registration Doc filed with the French Autorité des marchés financiers on April 20, 2021 (a duplicate of which is on the market at www.adocia.com) and to the event of financial circumstances monetary markets and the markets wherein Adocia operates. The forward-looking statements contained on this press launch are additionally topic to dangers not but identified to Adocia or not at the moment thought-about materials by Adocia. The prevalence of all or a part of such dangers may trigger precise outcomes, monetary circumstances, efficiency, or achievements of Adocia to be materially completely different from such forward-looking statements. This press launch and the data contained herein don’t represent a suggestion to promote or the solicitation of a suggestion to purchase Adocia shares in any jurisdiction.
1 2019 ADA – poster presentation, 7/11/2019
2 https://www.who.int/Information-Room/Truth-Sheets/Element/Weight problems-And-Chubby
3 Novo Nordisk 2020 Annual report